HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs
2
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Purpose: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneousadverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea. Materials and Methods: We enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01. Results: HLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessedHLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12–463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03–157.14; p=0.053). Among carbamazepine users, only two patients experiencedSJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03. Conclusion: HLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN.
Abstract
Purpose: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very serious forms of drug-induced cutaneousadverse reaction. SJS/TEN induced by certain drug is well known to be associated with some human leukocyte antigen (HLA) gene type. We aimed to explore HLA allele frequencies and their association with SJS/TEN according to culprit drugs in Korea. Materials and Methods: We enrolled 5802 subjects who had results of HLA typing test from August 2005 to July 2014. Total 28 SJS/TEN patients were categorized based on culprit drugs (allopurinol, lamotrigine, carbamazepine) and identified the presence of HLA-B*58:01, HLA-B*44:03, HLA-B*15:02, and HLA-A*31:01. Results: HLA-A*24:02 (20.5%), HLA-B*44:03 (10.0%), and HLA-Cw*01:02 (17.1%) were the most frequent type in HLA-A, -B, and -C genes, respectively. Allele frequencies of HLA-B*58:01, HLA-B*44:03, HLA-A*31:01, and HLA-B*15:02 were 7.0%, 10.0%, 5.0%, and 0.3%, respectively. In 958 allopurinol users, 9 subjects (0.9%) were diagnosed with SJS/TEN. Among them, 8 subjects possessedHLA-B*58:01 allele. SJS/TEN induced by allopurinol was more frequently developed in subjects with HLA-B*58:01 than in subjects without it [odds ratio: 57.4; confidence interval (CI) 7.12–463.50; p<0.001]. Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening. HLA-B*44:03 may be associated with lamotrigine-induced SJS/TEN (odds ratio: 12.75; CI 1.03–157.14; p=0.053). Among carbamazepine users, only two patients experiencedSJS/TEN and possessed neither HLA-B*15:02 nor HLA-A*31:03. Conclusion: HLA gene frequencies varied in Korea. Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN.
참고문헌 (40)
- Mockenhaupt M, "Epidemiology of cutaneous adverse drug reactions", Chem Immunol Allergy, 97, pp.1~17 (2012)
- Struck MF, "Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes", Intensive Care Med, 36, pp.22~32 (2010)
- Bastuji-Garin S, "Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme", Arch Dermatol, 129, pp.92~96 (1993)
- Sekula P, "Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis", J Invest Dermatol, 133, pp.1197~1204 (2013)
- Mockenhaupt M, "Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study", Invest Dermatol, 128, pp.35~44 (2008)
- Wei CY, "Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome", J Allergy Clin Immunol, 129, pp.1562~1569 (2012)
- Illing PT, "Immune self-reactivity triggered by drug-modified HLApeptide repertoire", Nature, 486, pp.554~558 (2012)
- Cao ZH, "HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese", Pharmacogenomics, 13, pp.1193~1201 (2012)
- Chiu ML, "Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong", Br J Dermatol, 167, pp.44~49 (2012)
- Lonjou C, "A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs", Pharmacogenet Genomics, 18, pp.99~107 (2008)
- Ganesan S, "Question 2 Should phenytoin and carbamazepine be avoided in Asian populations with the HLA-B*1502positive genetic variant?", Arch Dis Child, 96, pp.104~106 (2011)
- Genin E, "HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis", Pharmacogenomics J, 14, pp.281~288 (2014)
- Park HJ, "Clinical features of and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investigating the relation between the HLA -B*4403 allele and lamotrigine", Eur J Clin Pharmacol, 71, pp.35~41 (2015)
- Hung SI, "Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese", Pharmacogenomics, 11, pp.349~356 (2010)
- Jung JW, "HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insuffciency", Nephrol Dial Transplant, 26, pp.3567~3572 (2011)
- Kim SH, "Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans", Epilepsy Res, 97, pp.190~197 (2011)
- Kang HR, "Positive and negative associations of HLA class I alleles with allopurinolinduced SCARs in Koreans", Pharmacogenet Genomics, 21, pp.303~307 (2011)
- Huh JY, "HLA-A, -B and -DRB1 polymorphism in Koreans defined by sequence-based typing of 4128 cord blood units", Int J Immunogenet, 40, pp.515~523 (2013)
- 정혜윤, "Allelic and Haplotypic Diversity of HLA-A, -B, -C, and -DRB1 Genes in Koreans Defined by High-resolution DNA Typing", Annals of Laboratory Medicine, 30(6), pp.685~696 (2010), 대한진단검사의학회
- Trajanoski D, "HLA typing using bead-based methods", Methods Mol Biol, 882, pp.47~65 (2012)
- Mockenhaupt M, "Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management", Semin Cutan Med Surg, 33, pp.10~16 (2014)
- Balnyte R, "The importance of HLA DRB1 gene allele to clinical features and disability in patients with multiple sclerosis in Lithuania", BMC Neurol, 13, pp.77~ (2013)
- Dong DD, "Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer", Hum Immunol, 73, pp.998~1004 (2012)
- Phillips EJ, "HLA and drug-induced toxicity", Curr Opin Mol Ther, 11, pp.231~242 (2009)
- Phillips EJ, "Pharmacogenetics of drug hypersensitivity", Pharmacogenomics, 11, pp.973~987 (2010)
- Aihara M, "Pharmacogenetics of cutaneous adverse drug reactions", J Dermatol, 38, pp.246~254 (2011)
- 박형철, "Bronchiolitis Obliterans Associated with Stevens-Johnson Syndrome: A Case Report", Yonsei Medical Journal, 56(2), pp.578~581 (2015), 연세대학교의과대학[DOI]
- Mikuls TR, "New insights into gout epidemiology", Curr Opin Rheumatol, 18, pp.199~203 (2006)
- Pluim HJ, "The allopurinol hypersensitivity syndrome", Neth J Med, 52, pp.107~110 (1998)
- Halevy S, "Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel", J Am Acad Dermatol, 58, pp.25~32 (2008)
- Khanna D, "2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia", Arthritis Care Res (Hoboken), 64, pp.1431~1446 (2012)
- Chung WH, "Human leukocyte antigens and drug hypersensitivity", Curr Opin Allergy Clin Immunol, 7, pp.317~323 (2007)
- Tassaneeyakul W, "Strong association between HLA-B*5801and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population", Pharmacogenet Genomics, 19, pp.704~709 (2009)
- Ozeki T, "Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population", Hum Mol Genet, 20, pp.1034~1041 (2011)
- Yip VL, "HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review", Clin Pharmacol Ther, 92, pp.757~765 (2012)
- Kazeem GR, "High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients", Pharmacogenet Genomics, 19, pp.661~665 (2009)
- McCormack M, "Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions", Pharmacogenomics, 13, pp.399~405 (2012)
- Shi YW, "Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population", Basic Clin Pharmacol Toxicol, 109, pp.42~46 (2011)
- An DM, "Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population", Epilepsy Res, 92, pp.226~230 (2010)
- Lee KW, "Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population", Tissue Antigens, 65, pp.437~447 (2005)